Atria Investments’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $8.86M | Buy |
11,461
+29
| +0.3% | +$22.2K | 0.1% | 221 |
|
|
2025
Q4 | $8.82M | Sell |
11,432
-45
| -0.4% | -$30.6K | 0.1% | 223 |
|
|
2025
Q3 | $6.45M | Buy |
11,477
+8
| +0.1% | +$4.52K | 0.07% | 303 |
|
|
2025
Q2 | $6.02M | Buy |
11,469
+1,442
| +14% | +$805K | 0.07% | 323 |
|
|
2025
Q1 | $6.36M | Buy |
10,027
+3,390
| +51% | +$2.33M | 0.08% | 287 |
|
|
2024
Q4 | $4.73M | Sell |
6,637
-1,685
| -20% | -$1.41M | 0.06% | 370 |
|
|
2024
Q3 | $8.75M | Sell |
8,322
-281
| -3% | -$313K | 0.11% | 212 |
|
|
2024
Q2 | $9.04M | Sell |
8,603
-54
| -0.6% | -$52.3K | 0.12% | 190 |
|
|
2024
Q1 | $8.32M | Buy |
8,657
+941
| +12% | +$895K | 0.11% | 206 |
|
|
2023
Q4 | $6.76M | Buy |
7,716
+566
| +8% | +$466K | 0.1% | 227 |
|
|
2023
Q3 | $5.87M | Sell |
7,150
-420
| -6% | -$330K | 0.1% | 242 |
|
|
2023
Q2 | $5.43M | Sell |
7,570
-383
| -5% | -$295K | 0.1% | 241 |
|
|
2023
Q1 | $6.52M | Buy |
7,953
+295
| +4% | +$222K | 0.12% | 201 |
|
|
2022
Q4 | $5.52M | Sell |
7,658
-585
| -7% | -$432K | 0.11% | 225 |
|
|
2022
Q3 | $5.68M | Buy |
8,243
+324
| +4% | +$204K | 0.13% | 203 |
|
|
2022
Q2 | $4.68M | Sell |
7,919
-1,138
| -13% | -$740K | 0.1% | 244 |
|
|
2022
Q1 | $6.33M | Sell |
9,057
-992
| -10% | -$628K | 0.11% | 218 |
|
|
2021
Q4 | $6.35M | Buy |
10,049
+1,961
| +24% | +$1.21M | 0.11% | 221 |
|
|
2021
Q3 | $4.89M | Sell |
8,088
-349
| -4% | -$217K | 0.09% | 254 |
|
|
2021
Q2 | $4.71M | Buy |
8,437
+286
| +4% | +$145K | 0.09% | 252 |
|
|
2021
Q1 | $3.86M | Sell |
8,151
-2,053
| -20% | -$1,000K | 0.09% | 272 |
|
|
2020
Q4 | $4.93M | Sell |
10,204
-134
| -1% | -$72.3K | 0.12% | 199 |
|
|
2020
Q3 | $5.79M | Sell |
10,338
-7,088
| -41% | -$4.3M | 0.18% | 134 |
|
|
2020
Q2 | $10.9M | Buy |
17,426
+7,075
| +68% | +$4.02M | 0.37% | 60 |
|
|
2020
Q1 | $5.05M | Buy |
10,351
+2,616
| +34% | +$1.08M | 0.39% | 64 |
|
|
2019
Q4 | $2.9M | Buy |
7,735
+6,800
| +727% | +$2.29M | 0.08% | 221 |
|
|
2019
Q3 | $259K | Buy |
935
+107
| +13% | +$31.7K | 0.01% | 759 |
|
|
2019
Q2 | $248K | Buy |
828
+63
| +8% | +$21K | 0.01% | 812 |
|
|
2019
Q1 | $314K | Buy |
765
+42
| +6% | +$17.3K | 0.01% | 685 |
|
|
2018
Q4 | $270K | Sell |
723
-403
| -36% | -$148K | 0.01% | 690 |
|
|
2018
Q3 | $455K | Sell |
1,126
-371
| -25% | -$141K | 0.02% | 620 |
|
|
2018
Q2 | $516K | Buy |
1,497
+147
| +11% | +$46K | 0.02% | 564 |
|
|
2018
Q1 | $465K | Sell |
1,350
-580
| -30% | -$202K | 0.02% | 535 |
|
|
2017
Q4 | $726K | Buy |
1,930
+647
| +50% | +$262K | 0.04% | 403 |
|
|
2017
Q3 | $574K | Buy |
1,283
+115
| +10% | +$54.7K | 0.03% | 429 |
|
|
2017
Q2 | $574K | Buy |
1,168
+86
| +8% | +$37.6K | 0.04% | 400 |
|
|
2017
Q1 | $419K | Buy |
1,082
+120
| +12% | +$44.5K | 0.03% | 430 |
|
|
2016
Q4 | $353K | Buy |
962
+290
| +43% | +$110K | 0.03% | 421 |
|
|
2016
Q3 | $270K | Buy |
+672
| New | +$270K | 0.02% | 431 |
|
Other funds holding REGN
VCM
N
Atria Investments's REGN Position: Q1 2026 in Review
Atria Investments increased its Regeneron Pharmaceuticals (REGN) stake by 0.25% in Q1 2026, buying an estimated $22.2K and bringing the position to 11,461 shares worth $8.86M. The position accounts for 0.1% of the portfolio, ranked #221.
Atria Investments first reported a position in REGN in Q3 2016 and has held it in 39 quarters since. The position peaked at $10.9M in Q2 2020. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.
- Atria Investments held 11,461 shares of Regeneron Pharmaceuticals worth $8.86M as of Q1 2026.
- Atria Investments bought 29 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $22.2K.
- Regeneron Pharmaceuticals made up 0.1% of Atria Investments's portfolio in Q1 2026, its #221 holding.
- Atria Investments first reported a position in Regeneron Pharmaceuticals in Q3 2016 and has held it in 39 quarters since.
- Atria Investments's Regeneron Pharmaceuticals position peaked at $10.9M in Q2 2020.
- 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.
Based on Atria Investments's 13F filing for Q1 2026, filed 5 May 2026.